Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Videos|November 9, 2020
REL-1017: A New Treatment in the Works for Depression
Author(s)Maurizio Fava, MD
Learn about REL-1017, the medication that has the potential to be the first single agent oral NMDAR antagonist for the adjunctive treatment of depression.
Advertisement
Relmada Therapeutics just completed their phase II adjunctive major depressive disorder trial for their new medication dextromethadone (REL-1017), where they observed statistically significant anti-depressant effects, a favorable safety profile, and favorable tolerability. Maurizio Fava, MD, discusses the results and need-to-know information for REL-1017.
Dr Fava is chief of psychiatry at Massachusetts General Hospital and director of the division of clinical research for Massachusetts General Research Institute.
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Advertisement
Advertisement